NCT04435210View on ClinicalTrials.gov

Efficacy of Nifedipine Versus Hydralazine in Management of Severe Hypertension in Pregnancy

NACompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

August 13, 2018

Primary Completion Date

February 9, 2019

Study Completion Date

February 20, 2019

Conditions
Hypertension
Interventions
DRUG

Hydralazine

Participants in this group will receive 10mg of hydralazine intravenously. This will be repeated every 30 minutes if the blood pressure is equal to or more than 160/110 mmHg after the last dose, up to maximum of five doses.

DRUG

Nifedipine

Participants in this arm will receive 20mg of nifedipine and the blood pressure will be measured 30 minutes after the dose. This will be repeated every 30 minutes if the blood pressure is equal to or more than 160/110 mmHg after the last dose, up to maximum of five doses

Trial Locations (1)

840001

Alex Ekwueme Federal University Teaching Hospital, Abakaliki

All Listed Sponsors
lead

Adebayo Joshua Adeniyi

OTHER

NCT04435210 - Efficacy of Nifedipine Versus Hydralazine in Management of Severe Hypertension in Pregnancy | Biotech Hunter | Biotech Hunter